[ad_1] The U.S. government has secured 66 million doses of Moderna Inc’s MRNA COVID-19 vaccine booster candidate, mRNA-1273.222, a bivalent booster candidate containing Spikevax plus the omicron BA.4/5 strain mRNA. The contract…
[ad_1] Humana Inc HUM has posted Q2 adjusted sales of $23.72 billion, beating the consensus of $23.47 billion. The benefits expense ratio remained unchanged at 85.8%, and the operating cost…
[ad_1] Silk Road Medical Inc SILK posted Q2 revenue of $33.2 million, an increase of 25% Y/Y, driven primarily by increased TCAR adoption, beating the consensus of $31.16 million. “We…
[ad_1] Cidara Therapeutics Inc CDTX has submitted a marketing application to the FDA seeking approval for rezafungin for candidemia and invasive candidiasis. The company has also entered into a license agreement…
[ad_1] CinPax LLC has acquired around 4.1 million shares of vTv Therapeutics Inc VTVT at approximately $2.41 per share, with $6 million paid in cash at closing and the remaining $4 million payable on…
[ad_1] Citi group has initiated coverage on GSK plc’s GSK consumer healthcare spin-off Haleon Plc HLN with a Buy rating and a price target of 360p. “We see the company as the best…
[ad_1] ResMed Inc RMD has redesigned the AirSense 10 to eliminate a short-supply semiconductor chipset used for cellular communications chips. Instead of offering wireless communications capability, the new AirSense…
[ad_1] Here’s a roundup of top developments in the biotech space over the last 24 hours: VistaGen Therapeutics Inc VTGN has announced topline results from its PALISADE-1 Phase 3 trial of PH94B for…
[ad_1] by Vandana Singh, Benzinga Editor July 22, 2022 6:06 AM | 1 min read Same-hospital net patient service revenue per adjusted admission decreased 0.2% due to the cybersecurity incident.…
[ad_1] Quest Diagnostics Inc DGX posted a better-than-expected Q2 FY22 adjusted EPS of $2.36, though down 25.8% Y/Y, beating the consensus of $2.20. Sales came in at $2.45 billion, a…
[ad_1] Biogen Inc BIIB has posted Q2 sales of $2.59 billion, beating the consensus of $2.48 billion, down 7% Y/Y and 5% at constant currency (CC). Multiple sclerosis revenue, including…
[ad_1] Sanofi SA SNY has entered a deal to hand over 17 products to central nervous system (CNS) specialist Neuraxpharm for an undisclosed sum. The drugs comprise two product portfolios for…